RS54851B1 - Supstituisani 2-(hroman-6-iloksi)-tiazoli i njihova upotreba kao farmaceutskih sredstava - Google Patents
Supstituisani 2-(hroman-6-iloksi)-tiazoli i njihova upotreba kao farmaceutskih sredstavaInfo
- Publication number
- RS54851B1 RS54851B1 RS20160442A RSP20160442A RS54851B1 RS 54851 B1 RS54851 B1 RS 54851B1 RS 20160442 A RS20160442 A RS 20160442A RS P20160442 A RSP20160442 A RS P20160442A RS 54851 B1 RS54851 B1 RS 54851B1
- Authority
- RS
- Serbia
- Prior art keywords
- alkyl
- series consisting
- cycloalkyl
- substituted
- membered
- Prior art date
Links
- XFZODDHRWKDGLV-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-6-yloxy)-1,3-thiazole Chemical class C1=C2CCCOC2=CC=C1OC1=NC=CS1 XFZODDHRWKDGLV-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 18
- 125000001424 substituent group Chemical group 0.000 abstract 17
- 229910052757 nitrogen Inorganic materials 0.000 abstract 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 9
- 125000005842 heteroatom Chemical group 0.000 abstract 9
- 229910052760 oxygen Inorganic materials 0.000 abstract 9
- 239000001301 oxygen Substances 0.000 abstract 9
- 229910052717 sulfur Inorganic materials 0.000 abstract 9
- 239000011593 sulfur Substances 0.000 abstract 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 6
- 229910052731 fluorine Inorganic materials 0.000 abstract 6
- 239000011737 fluorine Substances 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000002950 monocyclic group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- -1 phenyl-O- Chemical class 0.000 abstract 2
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Jedinjenje formule I, u bilo kojem od svojih stereoizomernih oblika ili u smešistereoizomernih oblika u bilo kom odnosu, ili njegove farmaceutski prihvatljive soli,gdeAr je izabran iz serije koja se sastoji od fenila i 5-čanog ili 6-članog monocikličnog aromatičnog heterocikla, koji su svi nesupstituisani ili supstituisani sa jednim ili više identičnih ili različitih supstituentata R1, pri čemu heterocikl sadrži 1 ili 2 identična ili različita heteroatoma u prstenu, izabrana iz serije koja se sastoji od azota, kiseonika i sumpora i vezan je preko atoma ugljenika u prstenu; R1 je izabran iz serije koja se sastoji od halogena, (C1-C6)-alkil, (C3-C7)-cikloalkil, (C3-C7)-cikloalkil-(C1-C4)-alkil-, fenil, Het1, HO-, (C1-C6)-alkil-O-, (C3-C7)-cikloalkil-O-, (C3-C7)-cikloalkil-(C1-C4)-alkil-O-, fenil-O-, Hetl-O- i (C1-C6)-alkil-S(O)n-, i dve grupe R1 vezane za susedni atom ugljenika u prstenu u Ar, zajedno sa atomom ugljenika koji ih nosi, mogu da grade 5-člani do 7-člani mono-nezasićen prsten koji sadrži 0, 1 ili 2 identična ili različita heteroatoma u prstenu izabrana iz serije koja se sastoji od azota, kiseonika i sumpora, i koji je nesupstituisan ili supstituisan sa jednim ili više identičnih ilki različitih supstituenata izabranih iz serije koja se sastoji od fluora i (C1-C4)-alkila;R2 je izabran iz serije koja se sastoji od R5-N(R6)-C(O)-, R5-N(R6)-CH2-, R7-C(O)-NH-CH2- i R7-S(O)2-NH-CH2-;R3 je izabran iz serije koja se sastoji od vodonika, halogena, (C1-C4)-alkila i (C1-C4)-alkil-O-;R4 je vodonik ili jedan ili više identičnih ili različitih supstituenata izabranih iz serije koja se sastoji od halogen, (C1-C4)-alkil i (O-C4)-alkil-O-;R5 i R6 su nezavisno jedan od drugog izabrani iz serije koja se sastoji od vodonika , (C1-C6)-alkil, (C3-C7)-cikloalkil, (C6-C10)-bicikloalkil, fenil, Hetl i Het2, pri čemu (C1-C6)-alkil je nesupstituisan ili supstituisan sajednim ili više različitih supstituenata R10, i (C3-C7)-cikloalkil, (C6-C10)-bicikloalkil i Het2 su svi nesupstituisani ili supstituisani sajednim ili više različitih supstituenata R11, ili grupe R5 i R6, zajedno sa atomom azota koji ih nosi, grade 4-člani do 10-člani, monocikličan ili bicikličan, zasićen ili delimično nezasićen heterocikl koji, pored atoma azota koji nosi R5 i R6, sadrži 0 ili 1 dodatni heteroatom prstena izabran iz serije koja se sastoji od azota, kiseonika i sumpora, i koji je nesupstituisan ili supstituisan sa jednim ili više identičnih ili različitih supstituenata R12;R7 je izabran iz serije koja sadrži (C1-C6)-alkil, (C3-C7)-cikloalkil, fenil, Het2 i Het3, pri čemu (C1-C6)-alkil, (C3-C7)-cikloalkil i Het2 su svi nesupstituisani ili supstituisani sa jednim ili više identičnih ili različitih supstituenata R10, i fenil i Het3 su svi nesupstituisani ili supstituisani sa jednim ili više identičnih ili različitih supstituenata R13;R10 je izabran iz serije koja se sastoji od R14, fluora, HO-, okso, (C1-C6)-alkil-O-, R15-C(O)-O-, R15-NH-C(O)-O-, HO-S(O)2-O-, (HO)2P(O)-O-, (HO)2P(O)-O-CH2-O-C(O)-O-, (C1-C6)-alkil-S(O)n-, R16-N(R17)-, R18-C(O)-N(R17)-, R16-N(R17)-C(O)-. R19-O-C(O)- i R16-N(R17)-S(O)2-;R11 i R12 su nezavisno jedan od drugog izabrani iz serije koja se sastoji od (C1 -C4)-alkil, HO-(C1-C4)-alkil-, R16-N(R17)-(C1-C4)-alkil-, R19-O-C(O)-(C1-C4)-alkil-, R14, fluora, HO-, okso, (C1-C6)-alkil-O-, R15-C(O)-O-, R15-NH-C(O)-O-, HO-S(O)2-O-, (HO)2P(O)-O-, (HO)2P(O)-O-CH2-O-C(O)-O-, (C1-C6)-alkil-S(O)n-, R16-N(R17)-, R18-C(O)-N(R17)-, R16-N(R17)-C(O)-, R19-O-C(O)- i R16-N(R17)-S(O)2-;R13 je izabran iz serije koja se sastoji od halogena, (C1-C4)-alkil, HO-, (C1-C4)-alkil-O- i R16-N(R17)-, i dva supstituenta R13 vezana za susedni atom ugljenika u prstenu u R7, zajedno sa atomom ugljenika koji ih nosi, mogu da grade 5-člani do 7-člani mono-nezasićen prsten koji sadrži 0, 1 ili 2 identična ili različita heteroatoma izabrana iz serije koja se sastoji od azota, kiseonika i sumpora, i koji je nesupstituisan ili supstituisan sa jednim ili više različitih supstituenata koji su izabrani iz serije koja se sastoji od fluora i (C1-C4)-alkil,R14 je 3-člani do 10-člani, monocikličan ili bicikličan prsten koji je zasićen, delimično nezasićen ili aromatičan i sadrži 0, 1, 2, 3 ili 4 identična ili različita heteroatoma izabrana iz serije koja se sastoji od azota, kiseonika i sumpora, i koji je nesupstituisan ili supstituisan sa jednim ili više različitih supstituenata R20;R15 i R18 su nezavisno jedan od drugog izabrani iz serije koja se sastoji od (C1-C6)-alkil (C3-C7)-cikloalkil, (C3-C7)-cikloalkil-(C1-C4)-alkil-, fenil-(C1-C4)-alkil- i Het1-(C1-C4)-alkil-;R16 i R17 su nezavisno jedan od drugog izabrani iz serije koja se sastoji od vodonika, (C1-C6)-alkil, (C3-C7)-cikloalkil, (C3-C7)-cikloalkil-(C1-C4)-alkil-, fenil-(C1-C4)-alkil- i Hetl-(C1-C4)-alkil-,ili grupe R16 i R17. zajedno sa atomom azota koji ih nosi, grade 4-člani do 7-člani, monocikličan zasićen heterocikl koji, pored atoma azota koji nosi R16 i R17, sadrži 0 ili 1 dodatni heteroatom prstena izabran iz serije koja se sastoji od azota, kiseonika i sumpora, i koji je nesupstituisan ili supstituisan sajednim ili više identičnih ili različitih supstituenata koji su izabrani iz serije koja se sastoji od fluora i (C1-C4)-alkila;R19 je izabran iz serije koja se sastoji od vodonika, (C1-C6)-alkil, (C3-C7)-cikloalkil, (C3-C7)-cikloalkil-(C1-C4)-alkil-, fenil-(C1-C4)-alkil- i Hetl-(C1-C4)-alkil-;R20 je izabran iz serije koja se sastoji od halogena, (C1-C4)-alkil, HO-(C1-C4)-alkil-, (C3-C7)-cikloalkil, HO-, okso, (C1-C6)-alkil-O-, R15-C(O)-O-, R15-NH-C(O)-O-, HO-S(O)2-O-, (HO)2P(O)-O-, (HO)2P(O)-O-CH2-O-C(O)-O-, (C1-C6)-alkil-S(O)n-, R16-N(R17)-, R18-C(O)-N(R17)-, R18-O-C(O)-N(R17)-, NC-, R18-C(O)-, R16-N(R17)-C(O)-, R19-O-C(O)- i R16-N(R17)-S(O)2-;Het1 je 5-člani ili 6-člani monocikličan aromatičan heterocikl koji sadrži 1 ili 2 identična ili različita heteroatoma u prstenu, izabrana iz serije koja se sastoji od azota, kiseonika i sumpora, koji je nesupstituisan ili supstituisan sajednim ili više identičnih ili različitih supstituenata izabranih iz serije koja se sastoji od halogena, (C1-C4)-alkil i (C1-C4)-alkil-O-,Het2 je 4-člani do 10-člani monocikličan ili bicikličan, zasićen ili delimično nezasićen heterocikl koji sadrži 1 ili 2 identična ili različita heteroatoma izabrana iz serije koja se sastoji od azota, kiseonika i sumpora;Het3 je 5-člani do 10-člani monocikličan ili bicikličan aromatičan heterocikl koji sadrži 1 ili 2 identična ili različita heteroatoma izabrana iz serije koja se sastoji od azota, kiseonika i sumpora;n je izabran iz serije koja se sastoji od 0, 1 i 2, pri čemu svi brojevi n su nezavisni jedan od drugog;pri čemu sve fenil grupe, osim ako je drugačije naznačeno, su nesupstituisane ili supstituisane jednim ili više identičnih ili različitih supstituenata izabranih iz serije koja se sastoji od halogena, (C1-C4) alkila i -O-(C1-C4)-alkila;pri čemu sve cikloalkil i bicikloalkil grupe, nezavisno od bilo kojih drugih supstituenata koji mogu da budu prisutni na cikloalkil ili bicikloalkil grupi, mogu da budu supstituisane sa jednim ili više identičnih supstituenata koji su izabrani iz serije koja se sastoji od fluora i (C1-C4)-alkila;pri čemu sve alkil grupe, nezavisno od bilo kojih drugih supstituenata koji mogu da budu prisutni na alkil grupi, mogu da budu supstituisane sa jednim ili više fluor supstituenata;naznačeno time što je za upotrebu kao farmaceutsko sredstvo.Prijava sadrži još 30 patentnih zahteva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306128.7A EP2567958B1 (en) | 2011-09-12 | 2011-09-12 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
EP12756214.8A EP2755970B1 (en) | 2011-09-12 | 2012-09-10 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
PCT/EP2012/067622 WO2013037724A1 (en) | 2011-09-12 | 2012-09-10 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
RS54851B1 true RS54851B1 (sr) | 2016-10-31 |
Family
ID=46801528
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20150022A RS53748B1 (sr) | 2011-09-12 | 2011-09-12 | Supstituisani 2-(hroman-6-iloksi)-tiazoli i njihova upotreba kao farmaceutskih sredstava |
RS20160442A RS54851B1 (sr) | 2011-09-12 | 2012-09-10 | Supstituisani 2-(hroman-6-iloksi)-tiazoli i njihova upotreba kao farmaceutskih sredstava |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20150022A RS53748B1 (sr) | 2011-09-12 | 2011-09-12 | Supstituisani 2-(hroman-6-iloksi)-tiazoli i njihova upotreba kao farmaceutskih sredstava |
Country Status (28)
Country | Link |
---|---|
US (1) | US20140243292A1 (sr) |
EP (2) | EP2567958B1 (sr) |
JP (1) | JP5941986B2 (sr) |
AR (1) | AR087822A1 (sr) |
BR (1) | BR112014005518A2 (sr) |
CO (1) | CO6930365A2 (sr) |
CR (1) | CR20140130A (sr) |
CY (2) | CY1115953T1 (sr) |
DK (2) | DK2567958T3 (sr) |
EA (1) | EA027998B1 (sr) |
EC (1) | ECSP14013309A (sr) |
ES (2) | ES2528143T3 (sr) |
GT (1) | GT201400044A (sr) |
HK (1) | HK1182107A1 (sr) |
HR (2) | HRP20150025T1 (sr) |
HU (1) | HUE029233T2 (sr) |
MX (1) | MX343176B (sr) |
NI (1) | NI201400017A (sr) |
PE (1) | PE20141121A1 (sr) |
PL (2) | PL2567958T3 (sr) |
PT (2) | PT2567958E (sr) |
RS (2) | RS53748B1 (sr) |
SI (2) | SI2567958T1 (sr) |
TN (1) | TN2014000106A1 (sr) |
TW (1) | TWI549952B (sr) |
UA (1) | UA114407C2 (sr) |
UY (1) | UY34320A (sr) |
WO (1) | WO2013037724A1 (sr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5941637B2 (ja) * | 2011-09-12 | 2016-06-29 | サノフイ | 置換2−(クロマン−6−イルオキシ)−チアゾール及び医薬としてのその使用 |
TWI633095B (zh) * | 2013-03-08 | 2018-08-21 | 賽諾菲公司 | 經取代-6-基氧基-環烷類及其作為醫藥品之用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4168380A (en) | 1978-04-21 | 1979-09-18 | Hoffmann-La Roche Inc. | 7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid |
JPH0967336A (ja) | 1995-09-04 | 1997-03-11 | Kanebo Ltd | 新規なイソチオウレア誘導体 |
DK0978506T3 (da) | 1997-03-27 | 2003-02-24 | Taisho Pharmaceutical Co Ltd | 2-phenoxyanilinderivater |
WO2001017995A1 (en) | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2001295951A1 (en) | 2000-10-18 | 2002-04-29 | Senju Pharmaceutical Co. Ltd. | Novel 4-benzyloxyphenyl derivative and use thereof |
FI20011507A0 (fi) | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
AU2003244181A1 (en) | 2002-06-25 | 2004-01-06 | Yamanouchi Pharmaceutical Co., Ltd. | Phenoxypyridine derivative or salt thereof |
WO2004055280A1 (de) * | 2002-12-13 | 2004-07-01 | Hansgrohe Ag | Brausehalter |
FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
JP2006199941A (ja) * | 2004-12-20 | 2006-08-03 | Chisso Corp | クロマン環を有する化合物を含有する液晶組成物 |
WO2007073497A2 (en) * | 2005-12-22 | 2007-06-28 | Icagen, Inc. | Calcium channel antagonists |
JP5092111B2 (ja) | 2007-02-05 | 2012-12-05 | トーアエイヨー株式会社 | ブトキシアニリン誘導体 |
EP2103939A1 (en) | 2008-03-20 | 2009-09-23 | sanofi-aventis | Fluorescence based assay to detect sodium/calcium exchanger (NCX) "reverse mode" modulating compounds |
US8354454B2 (en) | 2008-10-01 | 2013-01-15 | Merck Sharp & Dohme Corp. | Prodrugs of oxazolidinone CETP inhibitors |
US8912224B2 (en) * | 2011-09-12 | 2014-12-16 | Sanofi | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
JP5941637B2 (ja) * | 2011-09-12 | 2016-06-29 | サノフイ | 置換2−(クロマン−6−イルオキシ)−チアゾール及び医薬としてのその使用 |
-
2011
- 2011-09-12 ES ES11306128.7T patent/ES2528143T3/es active Active
- 2011-09-12 EP EP11306128.7A patent/EP2567958B1/en active Active
- 2011-09-12 RS RS20150022A patent/RS53748B1/sr unknown
- 2011-09-12 PL PL11306128T patent/PL2567958T3/pl unknown
- 2011-09-12 DK DK11306128.7T patent/DK2567958T3/en active
- 2011-09-12 SI SI201130350T patent/SI2567958T1/sl unknown
- 2011-09-12 PT PT113061287T patent/PT2567958E/pt unknown
-
2012
- 2012-09-10 EA EA201490618A patent/EA027998B1/ru not_active IP Right Cessation
- 2012-09-10 JP JP2014529013A patent/JP5941986B2/ja active Active
- 2012-09-10 ES ES12756214.8T patent/ES2578184T3/es active Active
- 2012-09-10 PL PL12756214.8T patent/PL2755970T3/pl unknown
- 2012-09-10 RS RS20160442A patent/RS54851B1/sr unknown
- 2012-09-10 PE PE2014000332A patent/PE20141121A1/es active IP Right Grant
- 2012-09-10 DK DK12756214.8T patent/DK2755970T3/en active
- 2012-09-10 PT PT127562148T patent/PT2755970T/pt unknown
- 2012-09-10 HU HUE12756214A patent/HUE029233T2/en unknown
- 2012-09-10 MX MX2014002673A patent/MX343176B/es active IP Right Grant
- 2012-09-10 BR BR112014005518A patent/BR112014005518A2/pt not_active Application Discontinuation
- 2012-09-10 EP EP12756214.8A patent/EP2755970B1/en active Active
- 2012-09-10 AR ARP120103328A patent/AR087822A1/es unknown
- 2012-09-10 SI SI201230609A patent/SI2755970T1/sl unknown
- 2012-09-10 UA UAA201403780A patent/UA114407C2/uk unknown
- 2012-09-10 WO PCT/EP2012/067622 patent/WO2013037724A1/en active Application Filing
- 2012-09-11 TW TW101133072A patent/TWI549952B/zh not_active IP Right Cessation
- 2012-09-12 UY UY0001034320A patent/UY34320A/es not_active Application Discontinuation
-
2013
- 2013-08-13 HK HK13109436.8A patent/HK1182107A1/xx not_active IP Right Cessation
-
2014
- 2014-03-03 NI NI201400017A patent/NI201400017A/es unknown
- 2014-03-07 GT GT201400044A patent/GT201400044A/es unknown
- 2014-03-11 TN TNP2014000106A patent/TN2014000106A1/en unknown
- 2014-03-11 US US14/204,220 patent/US20140243292A1/en not_active Abandoned
- 2014-03-18 CR CR20140130A patent/CR20140130A/es unknown
- 2014-04-08 CO CO14075065A patent/CO6930365A2/es unknown
- 2014-04-11 EC ECSP14013309 patent/ECSP14013309A/es unknown
-
2015
- 2015-01-09 HR HRP20150025AT patent/HRP20150025T1/hr unknown
- 2015-01-23 CY CY20151100076T patent/CY1115953T1/el unknown
-
2016
- 2016-06-16 HR HRP20160687TT patent/HRP20160687T1/hr unknown
- 2016-06-28 CY CY20161100582T patent/CY1118141T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110451T1 (hr) | Upotreba izotiocijanata kao sredstva protiv mieloma | |
BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
UY30681A1 (es) | Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos. | |
UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
AR063942A1 (es) | Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c | |
ECSP10010178A (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
AR075717A1 (es) | Compuestos de 3- aril quinazolin -4- ona para combatir plagas de invertebrados | |
ECSP099451A (es) | Compuestos de urea policíclicos antibacterianos | |
AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
CO6390026A2 (es) | Derivados de isoxazol para uso como reguladores del crecimiento de plantas | |
ECSP099425A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2 | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
ES2623167T3 (es) | Pirroldicarboxamidas condensadas y su uso como productos farmacéuticos | |
AR062425A1 (es) | Formulacion de aerosol para la inhalacion de agonistas beta | |
UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros | |
UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones | |
BR112012013252A2 (pt) | composição farmacêutica tópica, preservativo, composto, e, uso do mesmo | |
DE602008004540D1 (de) | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydroindolizin-3-yl)acetamidderivate und verwandte verbindungen als antipilzmittel | |
AR047466A1 (es) | Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles. | |
AR079448A1 (es) | Inhibidores de la esfingosina quinasa |